Envoy Medical Inc Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
5-Yr Fwd EPS Growth
42.8%projected annual EPS growth
Analyst Coverage
2analysts covering
FY EPS (est.)
-$0.30next fiscal year
Reporting Calendar
| Event | Expected Date |
|---|---|
| Q3 2026 Earnings Release | 16 Nov 2026 |
Monitoring Framework
Key Performance Indicators
Pivotal Clinical Trial Enrollment (Acclaim Cochlear Implant) Quarterly56.0Target: 56 (Fully Enrolled)
Pivotal Clinical Trial Patient Activation Quarterly56.0Target: 56 (Fully Activated)
Global Patent Portfolio Count Quarterly47Target: Continuous Expansion
Watch Items
- Nasdaq $1.00 Minimum Bid Price ComplianceTrigger: Class A Common Stock trading below $1.00 for 30 consecutive business daysAction: Regain compliance by November 16, 2026, or face potential delisting procedures.
- 12-Month Endpoint Data Collection for Acclaim Cochlear ImplantTrigger: Completion of 12-month follow-up for all 56 patients (expected by April 2027)Action: Compile clinical data package to support the planned PMA submission to the FDA.
- Premarket Approval (PMA) Submission to the FDATrigger: Targeted submission timeline in Q2 2027Action: Submit formal PMA application to the FDA for the Acclaim fully implanted cochlear implant.
Research as of 20 Jun 2026